ERBB2 and triple-negative breast carcinoma: These include (i) the use of endocrine therapy for treatment of most HR positive tumors, (ii) Trastuzumab-based HER2-directed antibody therapy in addition to chemotherapy for treatment of HER2+ tumors and (iii) sole chemotherapy for treatment of Triple-negative Breast Cancer (TNBC).